(-0.12%) 5 207.25 points
(-0.02%) 39 018 points
(-0.16%) 18 170 points
(-0.89%) $77.68
(1.45%) $2.24
(-0.03%) $2 323.60
(-0.29%) $27.47
(-0.93%) $979.20
(0.09%) $0.930
(0.26%) $10.93
(0.13%) $0.800
(0.56%) $91.95
7.82% SEK 535.00
Live Chart Being Loaded With Signals
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally...
Stats | |
---|---|
Volumen de hoy | 181 236 |
Volumen promedio | 110 816 |
Capitalización de mercado | 30.83B |
EPS | SEK0 ( 2024-05-07 ) |
Próxima fecha de ganancias | ( SEK0 ) 2024-07-16 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | 71.43 |
ATR14 | SEK1.119 (0.21%) |
Volumen Correlación
Camurus AB (publ) Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Camurus AB (publ) Correlación - Moneda/Commodity
Camurus AB (publ) Finanzas
Annual | 2023 |
Ingresos: | SEK1.72B |
Beneficio Bruto: | SEK1.58B (92.06 %) |
EPS: | SEK7.78 |
FY | 2023 |
Ingresos: | SEK1.72B |
Beneficio Bruto: | SEK1.58B (92.06 %) |
EPS: | SEK7.78 |
FY | 2022 |
Ingresos: | SEK956.34M |
Beneficio Bruto: | SEK853.08M (89.20 %) |
EPS: | SEK1.010 |
FY | 2021 |
Ingresos: | SEK600.57M |
Beneficio Bruto: | SEK515.22M (85.79 %) |
EPS: | SEK-1.660 |
Financial Reports:
No articles found.
Camurus AB (publ)
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico